ArticleFrontiers in surgery2026
SPRAYDYE: a phase I/II randomised pilot study to assess the safety and feasibility of topically applied AKRO-6qcICG, a cathepsin-activatable fluorescent imaging agent, for real-time intraoperative resection margin assessment in breast-conserving surgery.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Introduction: The incidence of tumour-positive surgical resection margins (TPRMs) after breast-conserving surgery (BCS) remains high, ranging from 10 to 40%. A TPRM, defined as breast cancer cells at the edge of the resected specimen at pathological evaluation, implies residual tumour and necessitates re-resection or boost radiation. To prevent these additional treatments, intraoperative near-infrared (NIR) fluorescence imaging with the topically applied, fluorescently quenched, cathepsin-activatable imaging agent AKRO-6qcICG might be used to detect residual cancer in the surgical cavity and guide additional resection during BCS. Cathepsins are proteolytic enzymes that are upregulated by breast cancer (associated) cells and therefore are suitable targets for tumour imaging. Methods and analysis: A total of six healthy volunteers (Part A) and 16 breast cancer patients (Part B) will be enrolled. In Part A, AKRO-6qcICG will be topically applied randomly on drawn blisters in two doses as will the vehicle compound, and one blister will be untreated functioning as a negative control. Physician and subject will remain blinded. In Part B, a single dose of AKRO-6qcICG will be topically applied in the surgical cavity. The primary objective is, with the occurrence of treatment-emergent (serious) adverse events as primary outcome measure. Secondary outcome measures include local and systemic tolerability parameters such as wound healing, numeric rating scales of pain and pruritus, vital signs, electrocardiogram parameters, clinical laboratory tests and pharmacokinetic parameters. Among the exploratory outcome measures are the diagnostic accuracy of the imaging agent to detect residual tumour in the surgical cavity and the tumour-to-background ratio of the fluorescent signal. Ethics and dissemination: This protocol has been approved by the Medical Ethical Committee Leiden-Den Haag- Delft (METC- LDD). The protocol is registered at EU Clinical Trials Register number 2025-523166-24-00. The results of this study will be reported through peer- reviewed publications and conference presentations. Clinical Trial Registration: https://ctis.eu/trial/2025-523166-24-00?from=search.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.